Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Birgitte B. Rasmussen; Meredith M. Regan; Anne E. Lykkesfeldt; Patrizia Dell'Orto; Barbara Del Curto; Katrine L. Henriksen; Mauro G. Mastropasqua; Karen N. Price; Eliane Méry; Magali Lacroix-Triki; Stephen Braye; Hans J. Altermatt; Richard D. Gelber; Monica Castiglione-Gertsch; Aron Goldhirsch; Barry A. Gusterson; Beat Thürlimann; Alan S. Coates; Giuseppe Viale

doi:10.1016/S1470-2045(07)70386-8

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Birgitte B. Rasmussen, Meredith M. Regan, Anne E. Lykkesfeldt, Patrizia Dell'Orto, Barbara Del Curto, Katrine L. Henriksen, Mauro G. Mastropasqua, Karen N. Price, Eliane Méry, Magali Lacroix-Triki, Stephen Braye, Hans J. Altermatt, Richard D. Gelber, Monica Castiglione-Gertsch, Aron Goldhirsch, Barry A. Gusterson, Beat Thürlimann, Alan S. Coates, Giuseppe Viale

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article

Abstract

Background: The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III trial) has shown that letrozole significantly improves disease-free survival (DFS) compared with tamoxifen in postmenopausal women with endocrine-responsive early breast cancer. Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours. Methods: The BIG 1-98 trial consists of four treatment groups that compare 5 years of monotherapy with letrozole or tamoxifen, and sequential administration of one drug for 2 years followed by the other drug for 3 years. Our study includes data from the 4922 patients randomly assigned to the two monotherapy treatment groups (letrozole or tamoxifen for 5 years; 51 months median follow-up [range

Original language	English
Pages (from-to)	23-28
Number of pages	6
Journal	The Lancet Oncology
Volume	9
Issue number	1
DOIs	https://doi.org/10.1016/S1470-2045(07)70386-8
Publication status	Published - Jan 2008

Fingerprint

ASJC Scopus subject areas

Oncology

Cite this

Rasmussen, B. B., Regan, M. M., Lykkesfeldt, A. E., Dell'Orto, P., Del Curto, B., Henriksen, K. L., Mastropasqua, M. G., Price, K. N., Méry, E., Lacroix-Triki, M., Braye, S., Altermatt, H. J., Gelber, R. D., Castiglione-Gertsch, M., Goldhirsch, A., Gusterson, B. A., Thürlimann, B., Coates, A. S., & Viale, G. (2008). Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet Oncology, 9(1), 23-28. https://doi.org/10.1016/S1470-2045(07)70386-8

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer : supplementary results from the BIG 1-98 randomised trial. / Rasmussen, Birgitte B.; Regan, Meredith M.; Lykkesfeldt, Anne E.; Dell'Orto, Patrizia; Del Curto, Barbara; Henriksen, Katrine L.; Mastropasqua, Mauro G.; Price, Karen N.; Méry, Eliane; Lacroix-Triki, Magali; Braye, Stephen; Altermatt, Hans J.; Gelber, Richard D.; Castiglione-Gertsch, Monica; Goldhirsch, Aron; Gusterson, Barry A.; Thürlimann, Beat; Coates, Alan S.; Viale, Giuseppe.

In: The Lancet Oncology, Vol. 9, No. 1, 01.2008, p. 23-28.

Research output: Contribution to journal › Article

Rasmussen, BB, Regan, MM, Lykkesfeldt, AE, Dell'Orto, P, Del Curto, B, Henriksen, KL, Mastropasqua, MG, Price, KN, Méry, E, Lacroix-Triki, M, Braye, S, Altermatt, HJ, Gelber, RD, Castiglione-Gertsch, M, Goldhirsch, A, Gusterson, BA, Thürlimann, B, Coates, AS & Viale, G 2008, 'Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial', The Lancet Oncology, vol. 9, no. 1, pp. 23-28. https://doi.org/10.1016/S1470-2045(07)70386-8

Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet Oncology. 2008 Jan;9(1):23-28. https://doi.org/10.1016/S1470-2045(07)70386-8

Rasmussen, Birgitte B. ; Regan, Meredith M. ; Lykkesfeldt, Anne E. ; Dell'Orto, Patrizia ; Del Curto, Barbara ; Henriksen, Katrine L. ; Mastropasqua, Mauro G. ; Price, Karen N. ; Méry, Eliane ; Lacroix-Triki, Magali ; Braye, Stephen ; Altermatt, Hans J. ; Gelber, Richard D. ; Castiglione-Gertsch, Monica ; Goldhirsch, Aron ; Gusterson, Barry A. ; Thürlimann, Beat ; Coates, Alan S. ; Viale, Giuseppe. / Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer : supplementary results from the BIG 1-98 randomised trial. In: The Lancet Oncology. 2008 ; Vol. 9, No. 1. pp. 23-28.

@article{38b52364da61432db84296d88225fac3,

title = "Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial",

abstract = "Background: The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III trial) has shown that letrozole significantly improves disease-free survival (DFS) compared with tamoxifen in postmenopausal women with endocrine-responsive early breast cancer. Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours. Methods: The BIG 1-98 trial consists of four treatment groups that compare 5 years of monotherapy with letrozole or tamoxifen, and sequential administration of one drug for 2 years followed by the other drug for 3 years. Our study includes data from the 4922 patients randomly assigned to the two monotherapy treatment groups (letrozole or tamoxifen for 5 years; 51 months median follow-up [range ",

author = "Rasmussen, {Birgitte B.} and Regan, {Meredith M.} and Lykkesfeldt, {Anne E.} and Patrizia Dell'Orto and {Del Curto}, Barbara and Henriksen, {Katrine L.} and Mastropasqua, {Mauro G.} and Price, {Karen N.} and Eliane M{\'e}ry and Magali Lacroix-Triki and Stephen Braye and Altermatt, {Hans J.} and Gelber, {Richard D.} and Monica Castiglione-Gertsch and Aron Goldhirsch and Gusterson, {Barry A.} and Beat Th{\"u}rlimann and Coates, {Alan S.} and Giuseppe Viale",

year = "2008",

month = jan

doi = "10.1016/S1470-2045(07)70386-8",

language = "English",

volume = "9",

pages = "23--28",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "1",

}

TY - JOUR

T1 - Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer

T2 - supplementary results from the BIG 1-98 randomised trial

AU - Rasmussen, Birgitte B.

AU - Regan, Meredith M.

AU - Lykkesfeldt, Anne E.

AU - Dell'Orto, Patrizia

AU - Del Curto, Barbara

AU - Henriksen, Katrine L.

AU - Mastropasqua, Mauro G.

AU - Price, Karen N.

AU - Méry, Eliane

AU - Lacroix-Triki, Magali

AU - Braye, Stephen

AU - Altermatt, Hans J.

AU - Gelber, Richard D.

AU - Castiglione-Gertsch, Monica

AU - Goldhirsch, Aron

AU - Gusterson, Barry A.

AU - Thürlimann, Beat

AU - Coates, Alan S.

AU - Viale, Giuseppe

PY - 2008/1

Y1 - 2008/1

N2 - Background: The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III trial) has shown that letrozole significantly improves disease-free survival (DFS) compared with tamoxifen in postmenopausal women with endocrine-responsive early breast cancer. Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours. Methods: The BIG 1-98 trial consists of four treatment groups that compare 5 years of monotherapy with letrozole or tamoxifen, and sequential administration of one drug for 2 years followed by the other drug for 3 years. Our study includes data from the 4922 patients randomly assigned to the two monotherapy treatment groups (letrozole or tamoxifen for 5 years; 51 months median follow-up [range

AB - Background: The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III trial) has shown that letrozole significantly improves disease-free survival (DFS) compared with tamoxifen in postmenopausal women with endocrine-responsive early breast cancer. Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours. Methods: The BIG 1-98 trial consists of four treatment groups that compare 5 years of monotherapy with letrozole or tamoxifen, and sequential administration of one drug for 2 years followed by the other drug for 3 years. Our study includes data from the 4922 patients randomly assigned to the two monotherapy treatment groups (letrozole or tamoxifen for 5 years; 51 months median follow-up [range

UR - http://www.scopus.com/inward/record.url?scp=37549056583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549056583&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(07)70386-8

DO - 10.1016/S1470-2045(07)70386-8

M3 - Article

C2 - 18083065

AN - SCOPUS:37549056583

VL - 9

SP - 23

EP - 28

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 1

ER -

Access to Document

10.1016/S1470-2045(07)70386-8